BAY 1217389

Drug Profile

BAY 1217389

Alternative Names: BAY1217389

Latest Information Update: 21 Oct 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Bayer
  • Class 1 ring heterocyclic compounds; Antineoplastics; Small molecules
  • Mechanism of Action Cell death stimulants; TTK protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 25 Feb 2015 Bayer plans a phase I trial for Solid tumours (Late-stage disease, Second-line therapy or greater) in USA and Netherlands (NCT02366949)
  • 01 Feb 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in USA (PO, capsule)
  • 10 Jul 2013 BAY 1161909 is covered by patents in Canada, Europe, Israel, Ukraine and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top